Loading...
By Kelly Young
Edited by Lorenzo Di Francesco, MD, FACP, FHM
Apixaban may confer the lowest risk for upper gastrointestinal bleeding out of the oral anticoagulants — and bleeding risk can be further lowered with proton pump inhibitors (PPIs) — according to a retrospective study in JAMA.
Examining Medicare claims data, researchers identified 1.6 million people who started oral anticoagulant treatment over 5 years. Patients who received apixaban had the lowest risk for hospitalization for upper gastrointestinal bleeding (73 per 10,000 person-years), followed by warfarin (113 per 10,000), dabigatran (120 per 10,000), and rivaroxaban (144 per 10,000).
Bleeding risk was lower for each anticoagulant when a PPI was coprescribed, with the greatest reduction among dabigatran users. PPI prescriptions conferred the greatest risk reduction among patients with higher GI bleeding risk scores.
The authors conclude: "These findings may inform assessment of risks and benefits when choosing anticoagulant agents."
Comment
LINK(S):
JAMA article (Free)
Background: Physician's First Watch coverage of bleeding risk with newer oral anticoagulants (Free)